| Literature DB >> 23792896 |
Wei Wang1, Ming-He Cheng, Xiao-Hua Wang.
Abstract
Phytochemical investigation of the 70% EtOH extract of the leaves of Alstonia scholaris afforded seven new monoterpenoid indole alkaloids: scholarisins I-VII (1-7), and three known compounds: (3R,5S,7R,15R,16R,19E)-scholarisine F (8), 3-epi-dihydro- corymine (9), and (E)-16-formyl-5α-methoxystrictamine (10). Structural elucidation of all the compounds was accomplished by spectral methods such as 1D- and 2D-NMR, IR, UV, and HRESIMS. The isolated compounds were tested in vitro for cytotoxicity against seven tumor cell lines, anti-inflammatory activities against Cox-1 and Cox-2, and antifungal potential against five species of fungi. Compounds 1, 6, and 10 exhibited significant cytotoxicities against all the tested tumor cell lines with IC₅₀ values of less than 30 μM and selective inhibition of Cox-2 comparable with the standard drug NS-398 (>90%). Additionally, 1, 2, 3 and 8 showed antifungal activity against two fungal strains (G. pulicaris and C. nicotianae).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23792896 PMCID: PMC6269722 DOI: 10.3390/molecules18067309
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structures of compounds 1–10.
13C-NMR data of compounds 1–7 in CDCl3.
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| 2 | 107.5 | 105.6 | 107.0 | 103.5 | 104.9 | 102.0 | 186.7 |
| 3 | 85.4 | 85.1 | 85.3 | 51.9 | 51.1 | 70.6 | 50.8 |
| 5 | 86.1 | 85.6 | 85.9 | 105.4 | 106.9 | 63.5 | 89.7 |
| 6 | 42.5 | 44.4 | 42.9 | 42.8 | 40.9 | 42.5 | 43.6 |
| 7 | 55.1 | 53.1 | 55.5 | 52.3 | 52.4 | 62.4 | 53.2 |
| 8 | 131.5 | 131.6 | 133.1 | 138.0 | 136.8 | 131.3 | 142.4 |
| 9 | 126.0 | 126.0 | 126.1 | 122.7 | 123.4 | 121.6 | 121.6 |
| 10 | 121.5 | 122.1 | 121.9 | 119.9 | 120.0 | 127.5 | 124.9 |
| 11 | 128.9 | 128.6 | 128.9 | 128.1 | 128.5 | 130.6 | 125.4 |
| 12 | 110.7 | 110.4 | 110.3 | 109.1 | 110.2 | 112.5 | 120.8 |
| 13 | 147.9 | 148.3 | 147.8 | 144.6 | 145.9 | 148.7 | 156.1 |
| 14 | 25.0 | 28.5 | 23.6 | 26.2 | 27.0 | 34.2 | 35.8 |
| 15 | 34.1 | 33.5 | 37.3 | 27.7 | 28.3 | 34.2 | 33.4 |
| 16 | 65.6 | 54.4 | 55.0 | 52.8 | 52.1 | 65.6 | 58.8 |
| 17 | 197.4 | 65.9 | 66.2 | - | - | 194.5 | 63.0 |
| 18 | 13.4 | 13.7 | 13.6 | 12.8 | 12.9 | 15.1 | 13.5 |
| 19 | 120.7 | 119.7 | 119.8 | 58.4 | 58.5 | 133.2 | 127.8 |
| 20 | 130.5 | 131.3 | 131.3 | 61.5 | 61.6 | 129.9 | 137.7 |
| 21 | 47.9 | 48.1 | 48.2 | 44.7 | 44.5 | 66.6 | 50.5 |
| 168.0 | 169.3 | 169.4 | 172.1 | 172.6 | 171.9 | 169.1 | |
| CO2 | 52.7 | 51.5 | 51.7 | 51.8 | 51.6 | 53.9 | 51.4 |
| - | - | - | - | - | 50.5 | - | |
| OCH3 | 48.6 | 48.5 | 48.4 | 54.8 | 57.0 | - | 54.7 |
| - | - | 171.3 | - | - | - | - | |
| CO | - | - | 20.1 | - | - | - | - |
Figure 2Key HMBC () and NOESY () correlations of of compound 1.
Figure 3Key HMBC () and NOESY () correlations of of compound 4.
Figure 4Key HMBC () and NOESY () correlations of of compound 6.
Figure 5Key HMBC () and NOESY () correlations of of compound 7.
Cytotoxicity of compounds 1–10 against seven human tumor cell lines (IC50, μM) a.
| Compound | Cell lines | ||||||
|---|---|---|---|---|---|---|---|
| A-549 | BGC-823 | HepG2 | HL-60 | MCF-7 | SMMC-7721 | W480 | |
| 10.3 | 11.3 | 9.2 | 12.0 | 10.7 | 23.7 | 28.0 | |
| 52.7 | 61.8 | 49.0 | 59.4 | 54.3 | 59.7 | 59.5 | |
| 44.1 | 40.8 | 30.4 | 39.6 | 36.8 | 47.0 | 40.1 | |
| - | - | - | - | - | - | 94.9 | |
| 97.4 | - | - | - | - | 92.1 | - | |
| 13.0 | 12.9 | 10.8 | 12.3 | 11.3 | 24.9 | 29.9 | |
| 49.1 | 53.2 | 43.6 | 48.2 | 46.7 | 49.4 | 52.7 | |
| 47.8 | 51.5 | 44.8 | 50.7 | 48.9 | 53.2 | 51.4 | |
| 61.3 | 67.1 | 58.3 | 71.8 | 64.2 | 66.2 | 62.1 | |
| 16.1 | 15.7 | 14.8 | 17.2 | 14.7 | 31.2 | 35.5 | |
| Doxorubicin | 18.3 | 14.7 | 22.0 | 31.7 | 24.9 | 35.4 | 15.9 |
a Doxorubicin activities are expressed as IC50 values in nM, and those of compounds 1–8 are expressed as IC50 values in μM. (-) IC50 > 100 μM.
Evaluation of Anti-Inflammatory Activity of Compounds 1–10 a.
| Compound | COX-1 | COX-2 |
|---|---|---|
| 45.2 | 96.4 | |
| <0 | 14.9 | |
| 12.9 | 50.4 | |
| <0 | 21.1 | |
| <0 | 24.3 | |
| 36.9 | 95.5 | |
| <0 | 17.6 | |
| <0 | <0 | |
| 13.6 | 46.8 | |
| 38.5 | 92.0 | |
| SC-560 | 63.2 | |
| NS-398 | 97.1 |
a Percent inhibition (all compounds and reference drugs concentration: 100 μM).
Antifungal activities (zones of inhibition/and MIC mM, n = 3) of compounds 1–10.
| Compound | |||||
|---|---|---|---|---|---|
| 1 | 20/0.69 | - | 19/0.64 | - | - |
| 2 | 18/1.37 | - | 17/1.44 | - | - |
| 3 | 15/1.91 | - | 16/1.80 | - | - |
| 4 | - | - | - | - | - |
| 5 | - | - | - | - | - |
| 6 | - | - | - | - | - |
| 7 | - | - | - | - | - |
| 8 | 15/1.71 | - | 17/1.55 | - | - |
| 9 | - | - | - | - | - |
| 10 | - | - | - | - | - |
| Nystatin | 21/0.007 | 19/0.006 | 19/0.006 | 20/0.010 | 19/0.009 |
-: No activity.
1H-NMR data of compounds 1–7 in CDCl3 (δ in ppm and J in Hz).
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| 4.96 (s) | 4.98 (s) | 5.00 (s) | 5.04 (s) | 4.43 (s) | - | - | |
| 3 | - | - | - | 3.96 (m) | 3.36 (m) | 4.73 (dd, 14.0,4.0) | 4.48 (dd, 14.0,4.0) |
| 5 | - | - | - | - | - | 2.18 (m) | - |
| 5 | 4.88 (dd, 4.2,3.6) | 4.86 (d, 5.2) | 4.92 (dd, 4.0,3.6) | 5.28 (dd, 4.0,3.8) | 4.92 (dd, 7.2,5.6) | 2.32 (m) | 3.84 (dd, 4.0,3.8) |
| 6 | 2.25 (dd, 13.6,4.2) | 2.26 (d, 13.8) | 2.29 (d, 14.0) | 2.75 (dd, 14.0,4.0) | 2.76 (dd, 14.4,5.6) | 2.06 (m) | 2.20 (dd, 14.0,4.0) |
| 6 | 3.41 (dd, 13.6,3.6) | 3.48 (dd, 13.8,5.2) | 3.52 (dd, 14.0,5.2) | 3.08 (dd, 14.0,3.8) | 3.10 (dd, 14.4,7.2) | 2.33 (m) | 3.75 (dd, 14.0,3.8) |
| 9 | 7.31 (dd, 7.8,1.8) | 7.72 (dd, 8.2,2.0) | 7.76 (dd, 7.8,2.0) | 7.12 (dd, 8.2,1.8) | 7.14 (dd, 8.0,2.0) | 7.76 (dd, 7.8,2.0) | 7.79 (dd, 8.0,2.0) |
| 10 | 6.84 (dt, 7.8,1.8) | 6.70 (dt, 8.2,2.0) | 6.82 (dt, 7.8,2.0) | 6.78 (dt, 8.2,1.8) | 6.77 (dt, 8.0,2.0) | 6.92 (dt, 7.8,2.0) | 7.39 (dt, 8.0,2.0) |
| 11 | 7.08 (dt, 7.8,1.8) | 6.98 (dt, 8.2,2.0) | 7.14 (dt, 7.8,2.0) | 7.06 (dt, 8.2,1.8) | 7.10 (dt, 8.0,2.0) | 7.24 (dt, 7.8,2.0) | 7.14 (dt, 8.0,2.0) |
| 12 | 6.68 (dd, 7.8,1.8) | 6.66 (dd, 8.2,2.0) | 6.78 (dd, 7.8,2.0) | 6.56 (dd, 8.2,1.8) | 6.66 (dd, 8.0,2.0) | 6.79 (dd, 7.8,2.0) | 7.32 (dd, 8.0,2.0) |
| 14 | 2.26 (dd, 14.0,3.8) | 2.30 (dd, 14.0,3.8) | 2.33 (dd, 13.8,3.8) | 2.23 (m) | 2.25 (m) | 2.27 (m) | 2.88 (m) |
| 14 | 2.18 (dd, 14.0,4.0) | 2.27 (dd, 14.0,4.0) | 2.29 (dd, 13.8,4.0) | 1.91 (m) | 1.93 (m) | 2.24 (m) | 1.96 (m) |
| 15 | 3.63 (dd, 4.0,3.8) | 3.69 (dd, 4.0,3.8) | 3.72 (dd, 4.0,3.8) | 2.95 (dd, 4.0,3.8) | 2.97 (dd, 4.0,3.8) | 3.62 (dd, 4.0,3.8) | 3.66 (dd, 4.0,3.8) |
| 16 | - | - | - | 2.92 (d, 4.8) | 2.59 (d, 4.2) | - | - |
| 17a | 8.52 (s) | 3.32 (d, 13.8) | 3.87 (d, 13.6) | - | - | 8.55 (s) | 3.68 (d, 13.2) |
| 17b | - | 3.46 (d, 13.8) | 4.01 (d, 13.6) | - | - | - | 3.91 (d, 13.2) |
| 18 | 1.51 (d, 7.0) | 1.55 (d, 7.2) | 1.58 (d, 7.0) | 1.40 (d, 7.0) | 1.41 (d, 6.8) | 1.83 (d, 7.2) | 1.55(d, 7.0) |
| 19 | 5.47 (q, 7.0) | 5.48 (q, 7.2) | 5.50 (q, 7.0) | 2.93 (q, 7.0) | 2.95 (q, 6.8) | 5.86 (d, 7.2) | 5.54(d, 7.0) |
| 21 | 3.85 (d, 13.8) | 3.87 (d, 14.2) | 3.89 (d, 13.8) | 3.36 (d, 14.0) | 3.39 (d, 14.0) | 3.88 (d, 13.8) | 4.07 (d, 13.6) |
| 21 | 3.31 (d, 13.8) | 3.33 (d, 14.2) | 3.35 (d, 13.8) | 3.08 (d, 14.0) | 3.11 (d, 14.0) | 3.35 (d, 13.8) | 3.08 (d, 13.6) |
| CO2 | 3.69 (s) | 3.78 (s) | 3.82 (s) | 3.70 (s) | 3.67 (s) | 3.80 (s) | 3.71 (s) |
| - | - | - | - | 2.03 (s) | - | ||
| OCH3 | 3.50 (s) | 3.52 (s) | 3.53 (s) | 3.10 (s) | 3.41 (s) | - | 3.25 (s) |
| CO | - | - | 1.53 (s) | - | - | - |